Proton therapy is a new way of treating cancer in which radiation doses are delivered more precisely. This results in less damage to surrounding tissue and fewer side effects. Professor Marco van Vulpen is medical director of HollandPTC in Delft, where the social value of this therapy is studied. Van…

Is it a coincidence that three chemists from the same department have each independently received a ZonMw grant? 'No,' the researchers agree in unison. 'The role of chemistry in medical biology is becoming increasingly important, and we’ve worked hard to make this happen.'

Providing each cancer patient with the right treatment remains a challenge. Oncode Accelerator aims to change this by innovating the way we develop cancer treatments, thus ensuring the patient is at the heart of the process.

An impressive 12 researchers from Leiden University have been awarded an 800,000-euro grant by the Dutch Research Council (NWO). This will enable them to develop their own line of research over the next five years.

How do cells repair their damaged DNA—and what happens when that process is hindered and cancer arises? Sarah Moser has taken a closer look during her PhD, uncovering surprising insights that could help improve future cancer treatments.

RARE-NL, a new collaboration between university hospitals, hopes to find treatments for rare diseases. Professor Teun van Gelder is representing the LUMC in the initiative.

PhD candidate Sibel Bahtiri is one of the new Faces of Science. In videos and blogs, she will show what life is like as a young researcher.

Cancer immunotherapy represents a significant breakthrough in cancer treatment. However, tumors have numerous mechanisms by which they evade destruction by the immune system. It is therefore necessary to decipher and reverse these mechanisms in order to improve immunotherapies.

Researchers at the Universities of Amsterdam (Uva) and Leiden together with the Netherlands Cancer Institute and Oncode Institute have received a €10,6 million ERC Synergy Grant to develop innovative therapeutic approaches to target glioblastoma. This is a deadly primary brain tumour for which no curing…

Optimised antibiotic combinations can combat bacteria more effectively while also slowing the development of resistance. Scientists from five European countries are joining forces to identify such combinations and provide tools for others to do the same. The project is led by Professor Coen van Hasselt…

Polypeptide Therapeutic Solutions (PTS), a leader in the design, development and custom manufacturing of polyamino-acid based delivery systems for therapeutic drugs and the Leiden Academic Centre for Drug Research (LACDR) today announced a research collaboration to develop advanced drug delivery systems…

The Leiden University Medical Center (LUMC), the Danstem Institute from the University of Copenhagen and the Murdoch Children’s Research Institute in Melbourne have received 300m euros from the Novo Nordisk foundation. The aim of this new international consortium is to bring stem-cell based therapies…

Leiden University Medical Center (LUMC), as a partner in the reNEW consortium, is once again receiving tens of millions of euros for research into new treatments based on stem cells. The collaboration will receive a total of €150 million to develop new therapies in regenerative medicine.

Organs and tissues grown in the lab may in the future be able to cure people with organ failures. Micha Drukker, professor of Stem Cells, Developmental Biology and Technology for Innovative Drug Research, is convinced that the use of stem cells will make this possible. He will deliver his inaugural…

Arteriosclerosis bears great similarities to autoimmune diseases. Researchers from Leiden University show this in a new study they published in the renowned scientific journal Nature Cardiovascular Research. 'This discovery suggests that treatment methods for autoimmune diseases might also be effective…

During the Summer School Science Communication, you will learn everything about science communication.

PhD candidate Mengxu Zhang (Division of Systems Pharmacology and Pharmacy) published a comprehensive and important review on “The potential impact of CYP and UGT drug-metabolizing enzymes on brain target site drug exposure” in Drug Metabolism Reviews.

This week, we are hosting the ULLA workshop 2023. We are proud partner of the ULLA. It is the European University Consortium for Pharmaceutical Sciences in which LACDR participates for already 30 years.